vs
Side-by-side financial comparison of PLAYSTUDIOS, Inc. (MYPS) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
SOLENO THERAPEUTICS INC is the larger business by last-quarter revenue ($66.0M vs $55.4M, roughly 1.2× PLAYSTUDIOS, Inc.). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs -24.7%, a 64.1% gap on every dollar of revenue. SOLENO THERAPEUTICS INC produced more free cash flow last quarter ($43.5M vs $3.6M).
PLAYSTUDIOS, Inc. develops and publishes free-to-play social and casual casino games for mobile, desktop and social platforms. It operates a loyalty rewards program that lets players redeem in-game achievements for real-world benefits including travel, dining and event tickets, serving markets across North America, Europe and Asia Pacific.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
MYPS vs SLNO — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $55.4M | $66.0M |
| Net Profit | $-13.7M | $26.0M |
| Gross Margin | — | 98.3% |
| Operating Margin | -17.7% | 33.5% |
| Net Margin | -24.7% | 39.4% |
| Revenue YoY | -18.3% | — |
| Net Profit YoY | 38.9% | 134.0% |
| EPS (diluted) | $-0.12 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $55.4M | — | ||
| Q3 25 | $57.6M | $66.0M | ||
| Q2 25 | $59.3M | $32.7M | ||
| Q1 25 | $62.7M | — | ||
| Q4 24 | $67.8M | — | ||
| Q3 24 | $71.2M | — | ||
| Q2 24 | $72.6M | — | ||
| Q1 24 | $77.8M | — |
| Q4 25 | $-13.7M | — | ||
| Q3 25 | $-9.1M | $26.0M | ||
| Q2 25 | $-2.9M | $-4.7M | ||
| Q1 25 | $-2.9M | — | ||
| Q4 24 | $-22.4M | — | ||
| Q3 24 | $-3.1M | — | ||
| Q2 24 | $-2.6M | — | ||
| Q1 24 | $-567.0K | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 98.3% | ||
| Q2 25 | — | 97.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -17.7% | — | ||
| Q3 25 | -13.6% | 33.5% | ||
| Q2 25 | -5.9% | -20.0% | ||
| Q1 25 | -4.4% | — | ||
| Q4 24 | -33.1% | — | ||
| Q3 24 | -6.7% | — | ||
| Q2 24 | -5.5% | — | ||
| Q1 24 | -2.2% | — |
| Q4 25 | -24.7% | — | ||
| Q3 25 | -15.8% | 39.4% | ||
| Q2 25 | -5.0% | -14.4% | ||
| Q1 25 | -4.6% | — | ||
| Q4 24 | -33.1% | — | ||
| Q3 24 | -4.3% | — | ||
| Q2 24 | -3.6% | — | ||
| Q1 24 | -0.7% | — |
| Q4 25 | $-0.12 | — | ||
| Q3 25 | $-0.07 | $0.47 | ||
| Q2 25 | $-0.02 | $-0.09 | ||
| Q1 25 | $-0.02 | — | ||
| Q4 24 | $-0.18 | — | ||
| Q3 24 | $-0.02 | — | ||
| Q2 24 | $-0.02 | — | ||
| Q1 24 | $0.00 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $104.9M | $498.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $227.9M | $494.8M |
| Total Assets | $290.6M | $599.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $104.9M | — | ||
| Q3 25 | $106.3M | $498.9M | ||
| Q2 25 | $112.9M | $286.8M | ||
| Q1 25 | $107.1M | — | ||
| Q4 24 | $109.2M | — | ||
| Q3 24 | $105.2M | — | ||
| Q2 24 | $106.3M | — | ||
| Q1 24 | $127.0M | — |
| Q4 25 | $227.9M | — | ||
| Q3 25 | $238.9M | $494.8M | ||
| Q2 25 | $245.3M | $240.1M | ||
| Q1 25 | $244.1M | — | ||
| Q4 24 | $244.7M | — | ||
| Q3 24 | $265.2M | — | ||
| Q2 24 | $263.6M | — | ||
| Q1 24 | $288.4M | — |
| Q4 25 | $290.6M | — | ||
| Q3 25 | $299.2M | $599.9M | ||
| Q2 25 | $316.2M | $332.3M | ||
| Q1 25 | $313.8M | — | ||
| Q4 24 | $323.0M | — | ||
| Q3 24 | $330.6M | — | ||
| Q2 24 | $333.4M | — | ||
| Q1 24 | $357.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.7M | $43.5M |
| Free Cash FlowOCF − Capex | $3.6M | $43.5M |
| FCF MarginFCF / Revenue | 6.5% | 65.8% |
| Capex IntensityCapex / Revenue | 0.2% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | $25.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.7M | — | ||
| Q3 25 | $5.7M | $43.5M | ||
| Q2 25 | $13.6M | $-12.6M | ||
| Q1 25 | $3.3M | — | ||
| Q4 24 | $11.6M | — | ||
| Q3 24 | $14.6M | — | ||
| Q2 24 | $14.5M | — | ||
| Q1 24 | $5.0M | — |
| Q4 25 | $3.6M | — | ||
| Q3 25 | $5.4M | $43.5M | ||
| Q2 25 | $13.2M | $-12.6M | ||
| Q1 25 | $3.2M | — | ||
| Q4 24 | $11.5M | — | ||
| Q3 24 | $13.9M | — | ||
| Q2 24 | $12.8M | — | ||
| Q1 24 | $3.6M | — |
| Q4 25 | 6.5% | — | ||
| Q3 25 | 9.3% | 65.8% | ||
| Q2 25 | 22.3% | -38.6% | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 19.6% | — | ||
| Q2 24 | 17.6% | — | ||
| Q1 24 | 4.6% | — |
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.5% | 0.0% | ||
| Q2 25 | 0.7% | 0.0% | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 2.4% | — | ||
| Q1 24 | 1.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.67× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
